KATH JOHN CHARLES,HUANG QINHUA,RICHARDSON PAUL FRANCIS,SACH NEAL WILLIAM,BAILEY SIMON,BURKE BENJAMIN JOSEPH,COLLINS MICHAEL RAYMOND,CUI JINGRONG JEAN,DEAL JUDITH GAIL,HOFFMAN ROBERT LOUIS,JOHNSON TED
申请号：
NZ62790013
公开号：
NZ627900A
申请日:
2013.02.20
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed are compounds encompassed by formula I where the substituents are as defined herein and to pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such compounds and salts. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer. Examples of the compounds include (5R)-8-amino-3-fluoro-5,14,19-trimethyl-18,19-dihydro-7,11-(metheno)-pyrimido[2&rsquo,1&rsquo:2,3]imidazo[4,5-h][2,5,11]benzoxadiazacyclotetradecin-20(5H)-one and (10R)-7-amino-12-fluoro-10,16-dimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile.
